2756 related articles for article (PubMed ID: 18319394)
1. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Reaume KT; Regal RE; Dorsch MP
Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
[TBL] [Abstract][Full Text] [Related]
2. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
[TBL] [Abstract][Full Text] [Related]
3. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
Hermosillo AJ; Spinler SA
Ann Pharmacother; 2008 Jun; 42(6):790-805. PubMed ID: 18477734
[TBL] [Abstract][Full Text] [Related]
4. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
5. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
Toth PP
Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
[TBL] [Abstract][Full Text] [Related]
6. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
Fox KA; Mehta SR; Peters R; Zhao F; Lakkis N; Gersh BJ; Yusuf S;
Circulation; 2004 Sep; 110(10):1202-8. PubMed ID: 15313956
[TBL] [Abstract][Full Text] [Related]
7. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation.
Orford JL; Fasseas P; Melby S; Burger K; Steinhubl SR; Holmes DR; Berger PB
Am Heart J; 2004 Mar; 147(3):463-7. PubMed ID: 14999195
[TBL] [Abstract][Full Text] [Related]
9. Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
Spinler SA
Am J Manag Care; 2009 Mar; 15(2 Suppl):S42-7. PubMed ID: 19355808
[TBL] [Abstract][Full Text] [Related]
10. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
DeEugenio D; Kolman L; DeCaro M; Andrel J; Chervoneva I; Duong P; Lam L; McGowan C; Lee G; DeCaro M; Ruggiero N; Singhal S; Greenspon A
Pharmacotherapy; 2007 May; 27(5):691-6. PubMed ID: 17461704
[TBL] [Abstract][Full Text] [Related]
11. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.
Bhatt DL
Am J Cardiol; 2009 Feb; 103(3 Suppl):11A-19A. PubMed ID: 19166708
[TBL] [Abstract][Full Text] [Related]
12. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Aronow HD; Steinhubl SR; Brennan DM; Berger PB; Topol EJ;
Am Heart J; 2009 Feb; 157(2):369-74. PubMed ID: 19185647
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy.
Rossini R; Musumeci G; Lettieri C; Molfese M; Mihalcsik L; Mantovani P; Sirbu V; Bass TA; Della Rovere F; Gavazzi A; Angiolillo DJ
Am J Cardiol; 2008 Dec; 102(12):1618-23. PubMed ID: 19064015
[TBL] [Abstract][Full Text] [Related]
14. Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
Mohler ER
Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S1-6. PubMed ID: 19213065
[TBL] [Abstract][Full Text] [Related]
15. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
Vermeer NS; Bajorek BV
J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
[TBL] [Abstract][Full Text] [Related]
16. Current antiplatelet therapies: benefits and limitations.
Angiolillo DJ; Guzman LA; Bass TA
Am Heart J; 2008 Aug; 156(2 Suppl):S3-9. PubMed ID: 18657680
[TBL] [Abstract][Full Text] [Related]
17. An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events.
Terpening C
J Am Board Fam Med; 2009; 22(1):51-6. PubMed ID: 19124633
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet therapy for improving post-PCI outcomes: interpreting current treatment guidelines for optimal management of the post-ACS patient.
Cross J
Am J Manag Care; 2009 Mar; 15(2 Suppl):S48-53. PubMed ID: 19355809
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Best PJ; Steinhubl SR; Berger PB; Dasgupta A; Brennan DM; Szczech LA; Califf RM; Topol EJ;
Am Heart J; 2008 Apr; 155(4):687-93. PubMed ID: 18371477
[TBL] [Abstract][Full Text] [Related]
20. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
